Cancer Prevention

Cancer Prevention Pharmaceuticals (CPP) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic agents to reduce the risk of cancer and other diseases. The company's lead program, CPP-1X/sul, is a combination therapy of eflornithine and sulindac designed to prevent the progression of Familial Adenomatous Polyposis (FAP), a rare genetic condition that leads to colorectal cancer. CPP leverages its expertise in polyamine metabolism and inflammation pathways to target pre-cancerous conditions. By focusing on prevention and early intervention, the company aims to provide alternatives to invasive surgeries for high-risk patient populations.